Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients
Archives of Iranian Medicine · 2025
DOI: 10.34172/aim.33237 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Archives of Iranian Medicine, 2025. Verfasst von Mehdi Goodarzi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, Lichen Planus, Pyrroles. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Lichen planopilaris (LPP) is a rare, inflammatory condition leading to scarring alopecia, predominantly affecting middle-aged women. Traditional treatments have shown limited efficacy, highlighting the need for novel therapeutic approaches. Tofacitinib, a Janus kinase (JAK) inhibitor, has shown promise in treating various autoimmune diseases, including autoimmune dermatological disorders. This study aims to evaluate the efficacy of tofacitinib in treating patients with LPP.
Methods
We conducted a retrospective, single-center observational study at Shohadaye Tajrish Hospital, reviewing records of 74 patients with biopsy-confirmed LPP who had extensive and treatment-resistant disease. Patients were treated with tofacitinib 5 mg twice daily for at least 16 weeks. Efficacy was assessed using the LPP Activity Index (LPPAI), and adverse events were monitored.
Results
This study evaluated 74 patients with LPP, predominantly female (83.3%), with a mean age of 46.64±8.05 years. The mean LPPAI score significantly decreased from 4.61±1.26 before treatment to 1.73±1.68 after six months (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Mehdi Goodarzi, Sahar Dadkhahfar, Hamideh Moravvej
Zitieren
APA
Goodarzi, M., Dadkhahfar, S., Yahyaei, F., Razzaghi, Z., & Moravvej, H. (2025). Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients. Archives of Iranian Medicine. https://doi.org/10.34172/aim.33237
Vancouver
Goodarzi M, Dadkhahfar S, Yahyaei F, Razzaghi Z, Moravvej H. Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients. Archives of Iranian Medicine. 2025. doi:10.34172/aim.33237
BibTeX
@article{Goodarzi2025,
author = {Goodarzi, Mehdi and Dadkhahfar, Sahar and Yahyaei, Faranak and Razzaghi, Zahra and Moravvej, Hamideh},
title = {Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients},
journal = {Archives of Iranian Medicine},
year = {2025},
doi = {10.34172/aim.33237}
}
EUVIMED